Many Teens Report Misuse of Opiates, Sedatives

Aimee Simone, Assistant Editor
Published Online: Thursday, November 7, 2013
Follow Pharmacy_Times:
Almost 1 in 10 adolescent patients at an emergency department reported misusing opioids or sedatives, and few had a current home prescription for the medication they misused.

Approximately 10% of adolescents visiting the emergency department who were surveyed for a recent study admitted to misusing prescription opiates or prescription sedatives. Those who misused the medications were also more likely to engage in other risky behaviors.
 
The study, published online on October 28, 2013, in Pediatrics, estimated the prevalence of nonmedical prescription opiate and prescription sedative use in adolescents aged 14 to 20 visiting the emergency department at the University of Michigan Medical Center between September 2010 and September 2011 and identified characteristics associated with drug use. Participating patients completed a computerized survey that screened for prescription opiate and sedative misuse, which was defined as taking the drugs to get high, taking more than the prescribed amount, or taking medications prescribed to someone else. The survey also collected information on participants’ demographics, academic performance, and risk factors including dating violence, drinking after driving, and misuse of alcohol, marijuana, and cough syrup. The researchers also reviewed the participants’ past medical records to determine what medications they were taking and when they had previously visited the emergency department.
 
Of 2135 teens and young adults included in the study, 222 (10.4%) reported nonmedical use of either prescription opiates or sedatives. Among these patients, 185 (8.7%) reported opiate misuse, 115 (5.4%) reported sedative misuse, and 78 reported misuse of both. Only 14.6% of opiate misusers and 12.3% of sedative misusers had a current home prescription for the medication they misused. Just over half (50.4%) of those who misused sedatives and 42.2% of those who misused opiates were on public assistance, compared with 28.2% of those who did not report misusing the drugs. Those who misused opiates and sedatives were also more likely to have poor academic performance and to report all other risk factors when compared with those who did not abuse the drugs.
 
Both opiate and sedative misusers were more likely to have visited the emergency department previously in the past year. Teens who misused opiates were more likely to have received an intravenous or oral opioid during their visit and were more likely to receive a prescription opioid on discharge; approximately 1 in 7 patients who indicated opiate abuse received a prescription compared with 1 in 15 of those who did not indicate abuse.
 
The authors of the study suggest that screening and intervention efforts to prevent prescription misuse by adolescents should be increased in the emergency department, regardless of the reason for the visit.
 
“In addition to developing screening and intervention protocols, information-sharing technology could assist providers in improving and monitoring safe prescribing practices,” they write. “Additionally, patients who require intravenous opioids are at high risk for [nonmedical prescription opiate use] and providers should be careful to balance treating pain complaints with this increased risk for [nonmedical prescription opiate use].”
Related Articles
A new study led by researchers from the Center for Pediatric Genomic Medicine at Children’s Mercy-Kansas City proves that genomic diagnostic testing can directly impact the care of children and infants with neurologic disorders.
Stephanie Baker Justice, PharmD, BCPS, a pharmacy specialist in the emergency department at Charleston Area Medical Center, talks about medication error risk points pharmacists should watch out for.
Stephanie Baker Justice, PharmD, BCPS, a pharmacy specialist in the emergency department at Charleston Area Medical Center, gives tips on how to mitigate medication errors in the ED.
Mylan Inc. announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic versions of Pfizer's Celebrex® Capsules, which is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults.
Latest Issues
$auto_registration$